Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations

Table 2 Prevalence of the autoantibodies in chronic hepatitis B compared with chronic hepatitis C, autoimmune hepatitis, primary biliary cirrhosis, and healthy controls n (%)

	CHB (n = 325)		CHC (n = 71)		AIH (n = 11)		PBC (n = 71)		HC (n = 60)
	Pos.	P value	Pos.	P value	Pos.	P value	Pos.	P value	Pos.
Any autoantibody	189 (58.2)	0.211	47 (66.2)	0.004	11 (100.0)	< 0.001	71 (100.0)	< 0.001	4 (6.7)
ANA (IFA)	76 (23.4)	0.353	13 (18.3)	0.044	6 (54.5)	< 0.001	47 (66.2)	< 0.001	2 (3.3)
SMA (IFA)	10 (3.1)	1.000	2 (2.8)	1.000	0 (0.0)	0.220	0 (0.0)	0.373	0 (0.0)
AMA-M2 (LIA)	22 (6.8)	0.322	2 (2.8)	1.000	1 (9.1)	< 0.001	60 (84.5)	0.033	0 (0.0)
Anti-BPO (LIA)	23 (7.1)	0.124	1 (1.4)	1.000	1 (9.1)	< 0.001	60 (84.5)	0.034	0 (0.0)
Anti-Sp100 (LIA)	8 (2.5)	0.360	0 (0.0)	1.000	0 (0.0)	< 0.001	11 (15.5)	0.616	0 (0.0)
Anti-PML (LIA)	36 (11.1)	0.003	0 (0.0)	0.615	0 (0.0)	< 0.001	30 (42.3)	0.003	0 (0.0)
Anti-gp210 (LIA)	41 (12.6)	< 0.001	0 (0.0)	0.372	0 (0.0)	< 0.001	35 (49.3)	0.001	0 (0.0)
Anti-LKM-1 (LIA)	2 (0.6)	1.000	1 (1.4)	0.190	1 (9.1)	1.000	0 (0.0)	1.000	0 (0.0)
Anti-LC-1 (LIA)	10 (3.1)	0.707	1 (1.4)	0.810	1 (9.1)	0.901	3 (4.2)	0.373	0 (0.0)
Anti-SLA/LP (LIA)	7 (2.2)	0.360	0 (0.0)	1.000	0 (0.0)	0.555	3 (4.2)	0.602	0 (0.0)
Anti-Ro52 (LIA)	91 (28.0)	0.015	10 (14.1)	< 0.001	10 (90.9)	< 0.001	36 (50.7)	< 0.001	3 (5.0)

P < 0.05, CHB vs CHC, CHB vs AIH, CHB vs PBC, and CHB vs HC, respectively. CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; HC: Health controls; ANA: Anti-nuclear antibodies; AMA: Anti-mitochondrial antibodies; SMA: Smooth-muscle antibodies; anti-PML: Anti-promyelocytic leukemia protein; anti-LKM-1: Anti-liver kidney microsome type 1; anti-LC-1: Anti-liver cytosolic antigen type 1; anti-SLA/LP: Anti-soluble liver antigen/liver pancreas; IFA: Indirect immunofluorescence assay; LIA: Line immunoassay.